RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.84
-0.27 (-0.56%)
At close: 4:00PM EST

47.84 0.00 (0.00%)
After hours: 4:57PM EST

Stock chart is not supported by your current browser
Previous Close48.11
Open48.11
Bid47.54 x 200
Ask49.00 x 100
Day's Range47.15 - 48.26
52 Week Range44.02 - 91.35
Volume209,722
Avg. Volume407,382
Market Cap2.04B
Beta1.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube4 hours ago

    ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ultragenyx Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to RARE-US. Comparing the performance and risk of Ultragenyx Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
    Zacks3 days ago

    Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

    Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

  • Reuters5 days ago

    U.S. FDA approves Ultragenyx drug for rare enzyme disorder

    The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy. The drug is designed to treat patients with mucopolysaccharidosis type VII, or MPS VII, a condition caused by an enzyme deficiency that affects tissue and organs, including the heart, and stunts growth. The drug, Mepsevii, was given to 23 patients who were treated for up to 164 weeks, the FDA said.

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga5 days ago

    Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate

    After Heron Therapeutics Inc (NASDAQ: HRTX ), Bristol-Myers Squibb Co (NYSE: BMY ) and Dynavax Technologies Corporation (NASDAQ: DVAX ) found favor with the FDA, it's Ultragenyx Pharmaceutical Inc (NASDAQ: ...

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Capital Cube12 days ago

    ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ultragenyx Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to RARE-US. Comparing the performance and risk of Ultragenyx Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
    Capital Cube13 days ago

    Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Ultragenyx Pharmaceutical, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Ultragenyx Pharmaceutical, Inc. – BioMarin Pharmaceutical Inc. and Alexion Pharmaceuticals, Inc. (BMRN-US and ALXN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.20 ... Read more (Read more...)

  • The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

  • Associated Press14 days ago

    Ultragenyx reports 3Q loss

    The Novato, California-based company said it had a loss of $1.87 per share. The results matched Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was also ...

  • 5 Biotech and Pharma Stocks with Key FDA Catalysts this November
    Zacks18 days ago

    5 Biotech and Pharma Stocks with Key FDA Catalysts this November

    Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

  • Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?
    Simply Wall St.last month

    Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?

    Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), a biotechnology company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs
    Investor's Business Dailylast month

    How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs

    Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.

  • Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017
    Capital Cube2 months ago

    Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ultragenyx Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • American City Business Journals2 months ago

    ​After bidding war, North Bay drug maker snags gene therapy company for $151 million

    After weighing buyout offers from two biotechs, gene therapy company Dimension Therapeutics said Tuesday that it accepted the superior proposal — a $151 million deal from a North Bay company that will allow the company to maintain a New England presence. Novato-based Ultragenyx Pharmaceutical (RARE) will buy Dimension (DMTX) for $6 per share. "I am thankful for the hard work and dedication of our talented employees, and am confident they will continue to make valuable contributions as part of a larger organization," Dimension CEO Annalisa Jenkins said in a statement.

  • American City Business Journals2 months ago

    ​After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout

    After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Dimension (DMTX) said it had agreed to be acquired by California-based Ultragenyx Pharmaceutical (RARE) for $6 per share.

  • TheStreet.com2 months ago

    Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

    Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

  • American City Business Journals2 months ago

    RegenxBio declines to push forward on planned acquisition

    Rockville-based RegenxBio Inc. has opted to back away from a deal to buy Dimension Therapeutics Inc. (DMTX) after the Boston-area biotech received a better buyout offer. RegenxBio (RGNX) said Monday morning it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical (RARE), based in Novato, California, is now offering to Dimension Therapeutics, a Cambridge, Massachusetts, biotech that's struggled with its pipeline in the last year. In August, RegenxBio announced plans to buy Dimension in an all-stock transaction that valued the deal at $3.41 per share, or $86 million in all.

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE

  • Barrons.com2 months ago

    Gene Therapy: A Big Week for Many Names

    It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.

  • MarketWatch2 months ago

    UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid

    Dimension Therapeutics Inc. shares surged 38% in early afternoon trade Monday on news that Ultragenyx Pharmaceutical Inc. has proposed to buy all its outstanding common stock for $5.50 per share, or about ...

  • TheStreet.com2 months ago

    Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

    Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.

  • Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
    Zacks2 months ago

    Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

    Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE